Key result
AdipoRon, an adiponectin receptor agonist, shows potential as a novel therapeutic agent for cardiometabolic diseases by activating AMPK and PPARα signaling pathways in experimental animal models.
Why the study?
The physiological function, signal transduction, and potential role of the adiponectin receptor agonist AdipoRon in metabolic and cardiovascular diseases have not been clearly elucidated.
Preclinical evidence suggests AdipoRon, an adiponectin receptor agonist, has pleiotropic beneficial effects on cardiometabolic diseases via AMPK and PPARα pathways, warranting future human studies.
Hypothesis-generating for AdipoRon in cardiometabolic disease; leaves open human translation from animal models.
PURPOSE Adiponectin has beneficial effects on metabolic and cardiovascular disease. Adiponectin receptor agonist, AdipoRon was discovered in 2013 and it may play an important role in preventing and ameliorating cardiometabolic disease. However, the physiological function and signal transduction of AdipoRon are still under way, and the potential role of AdipoRon in metabolic and cardiovascular diseases has not been clearly elucidated. The purpose of this review is to provide basic knowledge for the potential role of AdipoRon in cardiometabolic disease. METHODS In this review, we summarized the previous studies (published between 2013 and 2019) investigating the effect of AdipoRon on metabolic and cardiovascular disease. RESULTS The previous evidences have shown that AdipoRon treatment exerted its pleiotropic actions on metabolism related tissue and organs including adipose tissue, skeletal and cardiac muscles, liver, kidney, and vascular beds. Activation of adiponectin receptors may be effective for the treatment of metabolic and cardiovascular diseases due in part to activation of AMPK and PPARα signaling pathway as adiponectin does. CONCLUSIONS In conclusion, AdipoRon can be a novel therapeutic agent for the cardiometabolic disease. However, all of previous studies were conducted using experimental animal models and it is needed to investigate the role of AdipoRon in metabolic and cardiovascular disease in human.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2019) conducted a review in Cardiometabolic disease. AdipoRon was evaluated. AdipoRon, an adiponectin receptor agonist, shows potential as a novel therapeutic agent for cardiometabolic diseases by activating AMPK and PPARα signaling pathways in experimental animal models.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: